文献速递主动脉疾病

糖尿病对EVAR术后腹主动脉瘤增长与再干预的保护作用

The Protective Effects of Diabetes Mellitus on Post-EVAR AAA Growth and Reinterventions.
PubMed 文献 · Ann Vasc Surg · 2017-03-14

该回顾性队列纳入993例腹主动脉瘤EVAR患者,按糖尿病状态分组比较。糖尿病组动脉瘤囊扩张比例显著低于非糖尿病组(13.11%对19.43%,模型估计0.3058,95%CI 0.0486-0.5629,P=0.0198),再干预有减少趋势;Cox回归显示糖尿病对再干预有显著保护作用(HR 0.697,P=0.0151)。

要点

  • 糖尿病与EVAR术后动脉瘤囊扩张减少显著相关。
  • 糖尿病对再干预有显著保护作用(HR 0.697,P=0.0151)。
  • 死亡率和内漏发生率在糖尿病与非糖尿病组无显著差异。

核心结论

  • 糖尿病虽合并更多高血压和冠心病,但EVAR术后长期动脉瘤囊扩张率更低。
  • 该队列中糖尿病趋向于降低EVAR术后再干预需求。

研究设计与样本

  • 回顾性队列研究,连续纳入1479例接受AAA EVAR患者,993例符合纳入标准。
  • 围术期人口学与合并症用t检验和卡方检验,EVAR术后结局用Probit多变量模型、Kaplan-Meier生存曲线和Cox回归分析。

主要发现

  • 糖尿病组冠心病(70.49%对60.76%,P=0.014)和高血压(90.16%对79.46%,P=0.0008)比例显著高于非糖尿病组。
  • Probit多变量分析(平均随访51个月)显示糖尿病组动脉瘤囊扩张显著减少(13.11%对19.43%,模型估计0.3058,95%CI 0.0486-0.5629,P=0.0198)。
  • 再干预有减少趋势(糖尿病组23.50%对非糖尿病组28.41%,模型估计0.1990,95%CI -0.0262至0.4243,P=0.0833)。
  • Cox回归中糖尿病对再干预有显著保护作用(HR 0.697,P=0.0151),对动脉瘤囊扩张有趋向显著性(HR 0.750,P=0.1961)。
  • 死亡率和内漏发生率等其余结局在糖尿病与非糖尿病组间无显著差异。

临床怎么用

  • 对于合并糖尿病的AAA患者,EVAR术后可预期较低的动脉瘤囊扩张和再干预风险。
  • 糖尿病状态可作为EVAR术后随访策略和再干预风险评估的参考因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to investigate the effect of diabetes on post-endovascular aneurysm repairs (EVARs) of abdominal aortic aneurysms (AAAs). METHODS: A total of 1,479 consecutive patients who underwent AAA EVAR were reviewed. The cohorts were divided based on their diabetes status and compared. Preoperative demographic and comorbidity data were analyzed using the t-test and chi-squared test, whereas post-EVAR outcomes were analyzed using Probit multivariate model, followed by Kaplan-Meier survival curve and Cox regression. RESULTS: Of our 1,479 patients, 993 met inclusion criteria. One hundred eighty-three were diabetics (18.4%) compared with 810 nondiabetics (81.6%). Coronary artery disease (CAD; diabetics: 70.49%, nondiabetics: 60.76%, P = 0.014) and hypertension (HTN; diabetics: 90.16%, nondiabetics: 79.46%, P = 0.0008) were the only comorbidities analyzed, including follow-up length, which had any significant differences between the diabetic and nondiabetic groups. Probit multivariate analysis using a combined cohort follow-up mean of 51 months showed a significant decrease in aneurysm sac enlargement in diabetic patients (diabetics: 13.11%, nondiabetics: 19.43%, model estimate: 0.3058; 95% confidence interval [CI]: 0.0486-0.5629, Pr > ChiSq = 0.0198) and trended toward significantly fewer reinterventions (diabetics: 23.50%, nondiabetics: 28.41%, model estimate: 0.1990; 95% CI: -0.0262 to 0.4243, Pr > ChiSq = 0.0833). In the Cox regressions, diabetes had a significant protective factor on reinterventions (hazard ratio [HR]: 0.697, Pr > ChiSq = 0.0151), and was trending toward significance for aneurysm sac enlargement (HR: 0.750, Pr > ChiSq = 0.1961). There was no significant difference across diabetic status in any other outcomes, including mortality and endoleak occurrence. CONCLUSIONS: Although a higher proportion of diabetic patients present with HTN and CAD, they have decreased long-term rates of aneurysm sac enlargement after EVAR. As a result, this cohort trends toward a lower need for reintervention after EVAR.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Png CYM, Tadros RO, Kang M, et al. The Protective Effects of Diabetes Mellitus on Post-EVAR AAA Growth and Reinterventions. Ann Vasc Surg. 2017. PMID: 28302476. doi:10.1016/j.avsg.2016.10.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。